Eagle Pharmaceuticals (EGRX): Notes From Management Meetings - RBC

September 21, 2016 7:00 AM EDT
Get Alerts EGRX Hot Sheet
Price: $65.99 +0.06%

Rating Summary:
    4 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade EGRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on Eagle Pharmaceuticals (NASDAQ: EGRX) after hosting two days of meetings with management.

Three key points include: 1) the pipeline is led by Ryanodex in EHS and ecstasy/meth

2) there is further "upside" from the bendamustine franchise

3) capital deployment remains a wildcard

The analyst believes EGRX has established a solid underlying cash flow base with upside to come from the pipeline, greater BENDEKA duration, and capital deployment. EPS for 2016-18E increases to $3.51, $4.31 and $5.39 and the price target goes to $80 from $78.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $64.95 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

RBC Capital

Add Your Comment